CINCINNATI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) ("Onconetix" or the “Company”) a commercial stage biotechnology company...
GARDEN CITY, N.Y., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a...
KOL Panel to Discuss Data from Dose Optimization Clinical Trial of CRB-701NORWOOD, Mass., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Corbus...
GW Cancer Center to initiate Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to...
UNIONDALE, NY, Sept. 22, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation...
Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response Rate (ORR) at the Highest Dose Level (100 µg) and...
MMRF continues to drive the critical global research collaborations that lead to scientific breakthroughs and improved patient outcomesNORWALK, Conn., Sept....
LOS ANGELES and CARLSBAD, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF”...
VANCOUVER, BC / ACCESS Newswire / September 19, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased...
VANCOUVER, BC / ACCESS Newswire / September 19, 2025 / Onco-Innovations Limited (CBOE CA:ONCO )(OTCQB:ONNVF )(Frankfurt:W1H) (WKN: A3EKSZ ) ("...
Annual event recognizes top digital health solutions and connects international thought leaders OLATHE, Kan., Sept. 19, 2025 /PRNewswire/ -- Garmin...
MESA, ARIZONA / ACCESS Newswire / September 19, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE), a pioneer in AI-powered...
, Taiwan, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company”, “Advanced Biomed”), a biotechnology company...
Lunsumio provides high and long-lasting response rates, with approximately two-thirds of patients with a complete response in remission after four...
OVATION 3 pivotal Phase 3 trial is currently advancing IMNN-001, with several patients being treated LAWRENCEVILLE, N.J., Sept. 19, 2025...
– Approval triggers $10 million cash milestone payment to Verrica – – YCANTH® approval in Japan addresses significant unmet need...
REYKJAVIK, Iceland, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and...
REYKJAVIK, ICELAND (September 19, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar...
NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies,...
Inmazeb® (atoltivimab, maftivimab, and odesivimab-ebgn) was the first treatment approved by the U.S. Food and Drug Administration (FDA) for Orthoebolavirus zairense,...